Skip to search formSkip to main contentSkip to account menu

odanacatib

Known as: (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)pentanamide 
An inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Biphenyl Compounds
Bone Resorption InhibitionCathepsins

Narrower (1)

MK-0822

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Certainties and Uncertainties About Denosumab Discontinuation
The subjects of optimal duration of osteoporosis treatment consequences of stopping osteoporosis 
2017
2017
Romosozumab - Promising or Practice Changing?
Over the past decade, the osteoporosis landscape has changed. Even though more treatment options are available, fewer… 
2017
2017
Identification of mouse cathepsin K structural elements that regulate the potency of odanacatib.
Cathepsin K (CatK) is the predominant mammalian bone-degrading protease and thus an ideal target for antiosteoporotic drug… 
Review
2014
Review
2014
Future directions for new medical entities in osteoporosis.
2013
2013
Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis—a double-blind, randomized, dose-finding study
SummaryThe efficacy and safety of oral placebo or odanacatib 10, 25, or 50 mg once weekly for 52 weeks were evaluated in a double… 
2012
2012
Effects of Odanacatib on Bone Mineralization Density Distribution in Thoracic Spine and Femora of Ovariectomized Adult Rhesus Monkeys: A Quantitative Backscattered Electron Imaging Study
Odanacatib (ODN) has been developed as a selective inhibitor of cathepsin K, the major cysteine protease in osteoclasts. In adult… 
2010
2010
The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.
Review
2010
Review
2010
New treatment modalities in osteoporosis.
OBJECTIVE To describe recently discovered agents for the management of osteoporosis. METHODS A literature review (PubMed search… 
2009
2009
Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Abstract Odanacatib (MK-0822, MK-822) is an orally administered cathepsin K inhibitor being developed by Merck & Co Inc, under… 
2009
2009
New opportunities in the management of prostate cancer–related bone complications
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)